Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…
FDA Approves Rituximab for Children with GPA & MPA
Intravenous rituximab can now be used to treat pediatric patients with GPA and MPA as young as two years old…
Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Stay the Course: How to Maintain Remission in Vasculitis
MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…
Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases
Recent research into rituximab-induced serum sickness (RISS) reinforces the understanding that patients generally recover quickly. However, the study also found patients with autoimmune disease, especially SLE, had a significantly higher risk for developing RISS than patients using rituximab to treat hematological malignancy…
Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…
In Wake of Lupus Trial Failure, New Research Attacks From Many Angles
CHICAGO—When Richard Furie, MD, was first asked to speak about lupus at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7, organizers suggested he discuss low disease activity and classification criteria. But Dr. Furie, a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y., and a veteran investigator…
Coding Corner Question: How to Bill a Rituximab Infusion Visit?
A 66-year-old female patient returns for a second infusion of rituximab for her diagnosis of rheumatoid arthritis in multiple sites. She is rheumatoid factor positive. She says the pain in her knees, elbows and neck has slightly improved. She rates the severity of her pain at a 7 on a 10-point scale, which is an…
Coding Corner Answer: How to Bill a Rituximab Infusion Visit?
Take the challenge. CPT Codes: 96413, 96415 x 3, J9312 x 5, 96375, J2920 Diagnoses: M05.79 Coding Rationale As of Jan. 1, 2019, the Healthcare Common Procedure Coding System (HCPCS) code for rituximab was changed from J9310 rituximab 100 mg, to the new HCPCS code J9312 (injection, rituximab, 100 mg). According to a Verywell Health…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »